TKTX reports pivotal Replagal data

Transkaryotic Therapies (TKTX) said that in a double-blind pivotal Phase II study of its Replagal in 15 Fabry disease patients, the product gave a 4.2% decrease in cardiac mass compared to an 8.8% inc...